Are We Missing Something About the Maximum Dosing of Botulinum Toxin Type A1 in Adult and Pediatric Patients with Spasticity?
Alessandro Picelli, Rita Di Censo, Stefano Tamburin, Nicola Smania, Mirko Filippetti · 2024
Read Are We Missing Something About the Maximum Dosing of Botulinum Toxin Type A1 in Adult and Pediatric Patients with Spasticity? by Alessandro Picelli, Rita Di Censo, Stefano Tamburin, Nicola Smania, Mirko Filippetti (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11728732.txt.
Description
Alessandro Picelli and co-authors question whether maximum doses of botulinum toxin for spasticity are set right in this 2024 paper. The toxin is a first-line treatment for stiff muscles in adults and children. Dose caps are given per body weight in the guidance. The authors raise three worries about those caps. First, the safety margin to a lethal dose looks relevant and worth stating. Second, adult and child dosing rules do not line up with each other.
Third, the child doses may not suit the patients they target. Average body weights drive part of their arithmetic. Spasticity care affects stroke survivors and children with cerebral palsy alike. Dosing rules shape both benefit and risk in clinic. The paper is a critical commentary, not a trial. It asks regulators and makers to show their work.
Catalog record
| CREATOR | Alessandro Picelli, Rita Di Censo, Stefano Tamburin, Nicola Smania, Mirko Filippetti |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |